Zogenix down 4% premarket after pricing equity offering

Zogenix (NASDAQ:ZGNX) has priced its public offering of 8.52M common shares at $23.50 per share, for expected gross proceeds of ~$200.2M.

Underwriters’ over-allotment is an additional 1,278,000 shares.

Net proceeds will be used for commercialization of FINTEPLA and MT1621, funding of future clinical trials, for working capital and general corporate purposes.

Closing date is March 6.

Shares are down 4% premarket.

Previously: Zogenix -2.5% amid proposed stock offering (March 3)

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload the CAPTCHA.